pharma · Diabetes Mellitus · Hemophilia A
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Phase 1 · small molecule · Schizophrenia
SPD489 (lisdexamfetamine dimesylate) is an oral small-molecule stimulant being evaluated by Takeda for schizophrenia treatment. Lisdexamfetamine dimesylate is a prodrug form of dexamphetamine, approved in the United States for attention-deficit/hyperactivity disorder (ADHD) across multiple generic and branded formulati
Internal code SPD489-119
SPD489 (lisdexamfetamine dimesylate) is an oral small-molecule stimulant being evaluated by Takeda for schizophrenia treatment. Lisdexamfetamine dimesylate is a prodrug form of dexamphetamine, approved in the United States for attention-deficit/hyperactivity disorder (ADHD) across multiple generic and branded formulations. The Phase 1 trial SPD489-119 (NCT01457339) was completed as of June 2021, representing Takeda's exploratory investigation into potential off-label psychiatric applications of this established compound.
The program remains in early-stage development with no disclosed mechanism of action or target specification for the schizophrenia indication. Regulatory status for schizophrenia use is not yet disclosed; however, the parent compound maintains FDA approval for ADHD through 24 distinct applications (NDAs and ANDAs) held by Takeda and multiple generic manufacturers including Mylan, Teva, Sandoz, and others. No next milestone, peak sales projections, or consensus analyst positioning has been disclosed.
This represents a repurposing strategy leveraging an existing, well-characterized pharmacological entity into a new therapeutic domain. The completion of Phase 1 dosing and safety work in 2021 suggests early-stage feasibility assessment rather than imminent advancement to pivotal efficacy trials. Commercial and clinical development trajectory beyond Phase 1 remains undisclosed.
Schizophrenia affects approximately 20 million people globally and represents a significant unmet medical need despite the availability of multiple antipsychotic classes. Current first-line therapies—including dopamine antagonists (risperidone, olanzapine, aripiprazole) and newer agents (lurasidone, brexpiprazole)—carry substantial tolerability burdens including metabolic syndrome, extrapyramidal side effects, and cognitive impairment. Negative symptoms and cognitive dysfunction remain particularly resistant to existing pharmacotherapy.
Stimulant-based approaches to schizophrenia are unconventional; amphetamines are typically contraindicated due to psychotomimetic risk. However, emerging preclinical and clinical evidence suggests that carefully dosed psychostimulants may modulate dopaminergic and noradrenergic pathways in ways complementary to antipsychotic monotherapy, potentially addressing cognitive deficits and negative symptoms. Takeda's Phase 1 investigation suggests internal confidence in a mechanistic rationale, though this remains speculative without disclosed MOA data.
The competitive landscape includes established antipsychotics (aripiprazole, paliperidone ER, iloperidone, clozapine) and emerging adjunctive agents (valbenazine for tardive dyskinesia, minocycline as neuroprotective augmentation). A successful schizophrenia indication for lisdexamfetamine would represent a significant repositioning and potentially address treatment-resistant populations or cognitive symptom clusters inadequately served by current options. Market relevance depends on efficacy, safety profile, and regulatory pathway clarity—currently undisclosed.
Drug Class: Sympathomimetic amine; prodrug of dexamphetamine.
Modality: Small molecule.
Route of Administration: Oral.
Mechanism of Action (Schizophrenia Program): Not yet disclosed.
Target: Not yet disclosed.
Related Therapies: Lisdexamfetamine dimesylate is FDA-approved for ADHD under multiple brand and generic formulations. Established antipsychotics in the competitive set include dopamine D2 antagonists (risperidone, olanzapine, aripiprazole, paliperidone, clozapine, amisulpride) and serotonin-dopamine modulators (brexpiprazole, lurasidone, asenapine).
First Approval (ADHD Indication): Lisdexamfetamine dimesylate received FDA approval for ADHD; the original NDA (NDA021977) and subsequent generic ANDAs document regulatory clearance. Approval dates for individual applications are not specified in the provided facts.
Patent Status: Not yet disclosed for the schizophrenia indication.
Also known as: schizophrenia 12, schizophrenia (disease), SCZD
A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
ClinicalTrials.gov lists 2,921 registered studies for Schizophrenia (AACT aggregate).
Phase breakdown: NA (1,441), PHASE4 (414), PHASE3 (377), PHASE2 (297), PHASE1 (276), PHASE1/PHASE2 (52), PHASE2/PHASE3 (42), EARLY_PHASE1 (22)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005090), Orphanet — schizophrenia, NCT00000371, NCT00000372, NCT00000374, NCT00000387, NCT00001192, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 1 Trial Completed
SPD489-119 (NCT01457339) Phase 1 trial completed; no efficacy or safety results disclosed.
The schizophrenia treatment landscape is dominated by established antipsychotics across multiple pharmacological classes. First-generation dopamine antagonists (haloperidol, chlorpromazine, fluphenazine) and second-generation agents (risperidone, olanzapine, quetiapine, aripiprazole, paliperidone, clozapine, amisulpride, asenapine, lurasidone, brexpiprazole, iloperidone, sertindole, zuclopenthixol, clotiapine, ziprasidone) represent the standard-of-care backbone. Takeda itself markets vortioxetine (an antidepressant) and ramelteon (a melatonin agonist), neither of which are primary antipsychotics.
Emerging adjunctive strategies include valbenazine (VMAT2 inhibitor for tardive dyskinesia, Neurocrine Biosciences) and minocycline (neuroprotective augmentation, Bright Minds Biosciences). Indivior's PERSERIS (risperidone subcutaneous monthly) represents a formulation innovation rather than a novel mechanism.
SPD489's proposed stimulant-based approach would be mechanistically distinct from dopamine antagonism, positioning it as a potential cognitive enhancer or negative symptom modifier rather than a primary antipsychotic. However, no clinical efficacy data in schizophrenia has been disclosed. The competitive advantage, if any, would depend on demonstrated superiority in cognitive domains, negative symptoms, or tolerability—currently unknown. Regulatory and commercial viability remain contingent on Phase 2 advancement and efficacy signals not yet reported.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PERSERIS | Indivior Pty Ltd | small_molecule | approved |
| Iloperidone | Vanda Pharmaceuticals Netherlands B.V. | small_molecule | approved |
| Paliperidone ER | Hospital Authority, Hong Kong | small_molecule | approved |
| Valbenazine | NEUROCRINE BIOSCIENCES INC | small_molecule | approved |
| Minocycline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Varenicline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| SULPIRIDE , QUETIAPINE , PERPHENAZINE , CLOTIAPINE , ZIPRASIDONE , HALOPERIDOL , SERTINDOLE , PALIPERIDONE , ZUCLOPENTHIXOL , CARIPRAZINE , LEVOMEPROMAZINE , LURASIDONE , BREXPIPRAZOLE , AMISULPRIDE , CLOZAPINE , CHLORPROMAZINE , RISPERIDONE , FLUPHENAZINE , PROMAZINE , ARIPIPRAZOLE , ASENAPINE , OLANZAPINE , FLUPENTIXOL | Disc Medicine | small_molecule | approved |
| Aripiprazole | Otsuka Beijing Research Institute | small_molecule | approved |
| Ramelteon | Takeda | small_molecule | approved |
| Vortioxetine | Takeda | small_molecule | approved |
| Clozapine | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Dexmedetomidine | BioXcel Therapeutics | small_molecule | approved |
| ZIPRASIDONE HYDROCHLORIDE | — | Dopamine D2 receptor antagonist | Approved |
| TRIFLUOPERAZINE HYDROCHLORIDE | — | D2-like dopamine receptor antagonist | Approved |
| THIOTHIXENE | — | Dopamine D2 receptor antagonist | Approved |
| SAMIDORPHAN L-MALATE | — | Delta opioid receptor partial agonist | Approved |
| RISPERIDONE | — | Serotonin 2a (5-HT2a) receptor antagonist | Approved |
| QUETIAPINE FUMARATE | — | Serotonin 2c (5-HT2c) receptor antagonist | Approved |
| PROCHLORPERAZINE | — | Dopamine D2 receptor antagonist | Approved |
| PERPHENAZINE | — | Dopamine D2 receptor antagonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Lisdexamfetamine dimesylate is FDA-approved for ADHD under NDA021977 (original new drug application) and 23 subsequent generic applications (ANDAs 202802, 202827, 202830, 202835, 202836, 211840, 214134, 214484, 214547, 215330, 215415, 215802, 216266, 216944, 217068, 217194, 217442, 218306, 218604, 218850, 218987, 219258) and NDA208510 and NDA219847. Approved manufacturers include Takeda Pharmaceuticals USA, Mylan, Teva, Sandoz, Hikma, Amneal, Apotex, and others. Specific approval dates for individual applications are not disclosed.
Schizophrenia Indication: Regulatory status for schizophrenia is not yet disclosed. No FDA filing, approval, or rejection has been reported.
European Medicines Agency (EMA): Not yet disclosed.
Pharmaceuticals and Medical Devices Agency (PMDA, Japan): Not yet disclosed.
National Medical Products Administration (NMPA, China): Not yet disclosed.
SPD489 (lisdexamfetamine dimesylate) is an oral stimulant medication being investigated by Takeda for schizophrenia treatment. It is a prodrug form of dexamphetamine already approved for ADHD.
No. Lisdexamfetamine dimesylate is FDA-approved only for ADHD. Regulatory status for schizophrenia use is not yet disclosed.
SPD489 is in Phase 1 development for schizophrenia. The Phase 1 trial (SPD489-119, NCT01457339) was completed as of June 2021.
Takeda Pharmaceutical Company is the sponsor of the SPD489 schizophrenia development program.
The mechanism of action for SPD489 in schizophrenia has not been disclosed.
The specific target for SPD489 in schizophrenia has not been disclosed.
SPD489 (lisdexamfetamine dimesylate) is administered orally.
Phase 1 trial results have not yet been reported. The trial was completed as of June 2021, but efficacy and safety data remain undisclosed.
Yes. Lisdexamfetamine dimesylate is FDA-approved for ADHD under multiple brand and generic formulations from manufacturers including Takeda, Mylan, Teva, Sandoz, and others.
FDA-approved manufacturers include Takeda Pharmaceuticals USA, Mylan, Teva, Sandoz, Hikma, Amneal, Apotex, Ascent Pharma, Azurity, Elite Labs, Granules, Lannett, MSN, Norwich, Prinston, Rhodes Pharma, SpecGx, and Sun Pharma.
No partner or licensee has been disclosed for the SPD489 schizophrenia program.
Current antipsychotics inadequately address cognitive deficits and negative symptoms in schizophrenia. SPD489's stimulant mechanism may theoretically enhance cognition, though this remains speculative without disclosed efficacy data.
SPD489 is a stimulant (sympathomimetic amine) rather than a dopamine antagonist, representing a mechanistically distinct approach. However, stimulants are typically contraindicated in psychotic disorders, making this approach unconventional.
Established competitors include dopamine antagonists (risperidone, olanzapine, aripiprazole, paliperidone, clozapine, amisulpride) and emerging adjunctive agents (valbenazine, minocycline). Takeda also markets vortioxetine and ramelteon in psychiatry.
The next expected milestone for SPD489 has not been disclosed. Phase 1 completion in June 2021 was the most recent reported milestone.
Projected peak sales have not been disclosed.
No consensus analyst positioning has been disclosed for SPD489.
SPD489 (Lisdexamfetamine dimesylate) → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Takeda's Phase 1 investigation of lisdexamfetamine dimesylate for schizophrenia represents a speculative repurposing strategy leveraging an existing, well-characterized compound with established manufacturing and safety data. This approach reduces preclinical and early development risk but faces significant regulatory and clinical hurdles: stimulants are typically contraindicated in psychotic disorders due to psychotomimetic potential. The absence of disclosed mechanistic rationale or Phase 1 safety/efficacy data limits assessment of program viability.
Competitive Implications: If efficacy is demonstrated, SPD489 would occupy a mechanistically distinct niche as a potential cognitive enhancer or negative symptom modifier rather than a primary antipsychotic. However, the crowded antipsychotic market and established adjunctive strategies (valbenazine, minocycline) suggest limited commercial differentiation without clear clinical superiority. Takeda's existing psychiatric portfolio (vortioxetine, ramelteon) does not directly compete but reflects broader CNS strategy.
Future Catalysts: Phase 2 initiation and efficacy readout (if disclosed); regulatory guidance on schizophrenia indication pathway; safety signals or tolerability data from Phase 1; potential partnership or out-licensing announcements.
Expected Milestones: Not yet disclosed. Phase 1 completion (June 2021) was the most recent disclosed milestone; no next milestone date or label has been announced.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.